Stockreport

Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]

Immunovant, Inc.  (IMVT) 
PDF Play 8min Summary Immunovant, Inc. switched focus from batoclimab to IMVT-1402, an anti-FcRn monoclonal antibody, to avoid cholesterol-related side effects. IMV [Read more]